[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

![GeneOnlineNews Avatar](https://lunarcrush.com/gi/w:24/cr:twitter::889321711966998528.png) GeneOnline [@GeneOnlineNews](/creator/twitter/GeneOnlineNews) on x 4755 followers
Created: 2025-07-24 11:04:43 UTC

During BIO Asia–Taiwan 2025, GeneOnline visited PharmaEssentia, a global biopharmaceutical company known for developing innovative therapies for hematologic malignancies, cancers, and immune-related diseases. 

The company outlined its four strategic pillars for growth: 
1) Ropeginterferon alfa-2b (BESREMi®), a long-acting mono-pegylated interferon already approved for polycythemia vera in the U.S., EU, and Asia
2) a growing immune-oncology pipeline featuring anti-TIM-3 and anti-PD-1 checkpoint inhibitors
3) its proprietary PEGylation platform for creating long-acting biologics

Stay informed throughout BIO Asia–Taiwan 2025. Subscribe to GeneOnline’s newsletter for daily on-the-ground reporting, expert insights, and exclusive interviews:

#BIOAsiaTaiwan #PharmaEssentia #BESREMi #ImmunoOncology #CheckpointInhibitors #TCRTherapy #BiotechLeadership #GeneOnline

![](https://pbs.twimg.com/media/GwnjfU2bwAAcFi6.jpg)

XX engagements

![Engagements Line Chart](https://lunarcrush.com/gi/w:600/p:tweet::1948338551248310716/c:line.svg)

**Related Topics**
[$6446tw](/topic/$6446tw)
[$issc](/topic/$issc)

[Post Link](https://x.com/GeneOnlineNews/status/1948338551248310716)